SCHEMBL13628288

SCHEMBL13628288

COc1ccc(-c2ccc3c(c2)N(Cc2cc(F)cc4c2OCOC4)C(=O)/C3=N\O)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ACE P12821 1/20 0.34
POLB P06746 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CHRM5 P08912 2/20 0.33
GALR3 O60755 1/20 0.33
NR2F2 P24468 1/20 0.33
MAPK8 P45983 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LTC4S Q16873 1/20 0.33
HCRTR1 O43613 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628077 0.93 TSHR (0.38) TSHRCYP3A4CYP2C9CYP2C19MAPT
SCHEMBL13628292 0.92 TSHR (0.43) TSHRCYP3A4CYP2C9CYP2C19MAPT
SCHEMBL13628295 0.91 POLB (0.36) TSHRCYP3A4CYP2C9CYP2C19MAPT
SCHEMBL13628065 0.91 NPC1 (0.37) TSHRCYP3A4CYP2C9CYP2C19TDP1
SCHEMBL13910801 0.89 POLB (0.36) TSHRCYP3A4CYP2C9CYP2C19MAPT
SCHEMBL13628324 0.89 TSHR (0.39) TSHRCYP3A4CYP2C9CYP2C19MAPT
SCHEMBL13628296 0.88 POLB (0.34) TSHRTDP1POLBNPSR1NPC1
SCHEMBL13628289 0.88 ALDH1A1 (0.37) TSHRCYP3A4CYP2C9CYP2C19MAPT
SCHEMBL13628290 0.88 POLB (0.34) TSHRTDP1POLBNPSR1NPC1
SCHEMBL13628070 0.87 NPC1 (0.36) TSHRCYP3A4CYP2C9CYP2C19TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 TSHR 4286/4885CYP3A4 4800/4885CYP2C9 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.